Want to see OM full AI Analyst Report?
Top Page
Outset Medical
(NASDAQ:OM)
Select Model
Select Model
Rating:54Neutral
Price Target:
$4.50
▲(3.45% Upside)
Action:Reiterated
Date:06/19/26
The score is held back primarily by ongoing deep unprofitability and negative free cash flow despite improved margins and a stronger balance sheet. Technicals are moderately supportive (above key short/medium DMAs with positive MACD) and recent updates were constructive (reaffirmed guidance, margin expansion, improved cash-use outlook), with the HCA multi-year agreement adding visibility, but execution risk remains due to soft recent revenue and reliance on back-half growth timing.
Positive Factors
Recurring revenue base (~70%)
Consumables and service revenue comprising roughly 70% of sales creates an annuity-like stream tied to treatments and installed consoles. This durable pull-through reduces top-line volatility, supports predictable margins and cash flow as installed base scales over quarters and years.
Negative Factors
Deep unprofitability and cash burn
Persistent heavy losses and negative free cash flow create ongoing funding and execution risk. Even with margin gains, continued negative cash conversion requires either sustained external financing or rapid margin and revenue improvement to avoid dilution or constrained growth options.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue base (~70%)
Consumables and service revenue comprising roughly 70% of sales creates an annuity-like stream tied to treatments and installed consoles. This durable pull-through reduces top-line volatility, supports predictable margins and cash flow as installed base scales over quarters and years.
Read all positive factors
Outset Medical (OM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$79.99M
Dividend YieldN/A
Average Volume (3M)205.25K
Price to Earnings (P/E)―
Beta (1Y)1.90
Revenue Growth2.01%
EPS Growth85.71%
CountryUS
Employees354
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-4.16
Shares Outstanding18,537,241
10 Day Avg. Volume200,402
30 Day Avg. Volume205,247
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.47
P/FCF Ratio-1.20
Enterprise Value/Market Cap1.82
Enterprise Value/Revenue1.24
Enterprise Value/Gross Profit3.05
Enterprise Value/Ebitda-2.55
Forecast
1Y Price Target
$7.67Price Target Upside76.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$126.77M
Outset Medical Business Overview & Revenue Model
Company Description
Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments...
How the Company Makes Money
Outset Medical primarily generates revenue by selling and deploying its Tablo Hemodialysis System and associated recurring consumables and services required to run dialysis treatments. Key revenue streams generally include: (1) product revenue fro...
Outset Medical Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call presented a largely positive operational and financial trajectory: substantial gross margin expansion (620 bps), a 32% improvement in non-GAAP net loss, strong cash balance ($161M) with lower-than-expected cash burn, and a strategic next-generation product and experienced commercial hire poised to drive future demand. Offsetting these positives were a 6% year-over-year revenue decline in Q1 driven by lumpiness in capital orders (product revenue down 13%), modestly higher operating expenses, and reliance on the timing and success of the next-gen Tableau launch to deliver back-half revenue. On balance, the positive margin, cash, and operational execution updates outweigh the timing-related revenue headwinds.Positive Updates
Revenue and Guidance Reaffirmed
Q1 revenue of $27.9M and company reaffirmed 2026 revenue guidance of $125M–$130M (a 5%–9% increase over 2025), with majority of growth expected in Q3–Q4.
Negative Updates
Quarterly Revenue Decline and Product Sales Drop
Q1 revenue declined 6% year-over-year to $27.9M from $29.8M. Product revenue fell 13% to $18.6M, and capital sales were $5.4M, reflecting timing variability.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue and Guidance Reaffirmed
Q1 revenue of $27.9M and company reaffirmed 2026 revenue guidance of $125M–$130M (a 5%–9% increase over 2025), with majority of growth expected in Q3–Q4.
Read all positive updates
Company Guidance
Outset reaffirmed 2026 guidance of $125–$130 million in revenue (up 5%–9% vs. 2025), noting Q1 revenue of $27.9M (down 6% YoY) with product revenue $18.6M (down 13%), capital sales $5.4M, consumables $13.2M and service & other $9.3M (up 10%); recurring consumables + service revenue was $22.5M and comprises roughly 70% of total revenue. Q2 is expected to be a modest step-up with the majority of the year’s growth in Q3–Q4 (helped by next‑generation Tableau), and full‑year non‑GAAP gross margin is guided to the low‑ to mid‑40% range (Q1 non‑GAAP gross margin was 43.8%, +620 bps YoY; product margin 52.4%, +400 bps; service margin 26.7%, +~1,640 bps), with company aiming toward a 50% company‑wide gross‑margin milestone. Non‑GAAP operating expenses were $25.6M (+~4%), non‑GAAP operating loss was $13.4M (flat YoY) and non‑GAAP net loss improved to $15.4M (‑32% YoY); balance sheet cash was $161M, Q1 cash use was ~$12M, and management now expects full‑year cash use of < $40M (about 15% better than prior expectation).Outset Medical Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 117.59M | 119.48M | 113.69M | 130.38M | 115.38M | 102.60M |
| Gross Profit | 47.78M | 46.75M | 38.56M | 29.00M | 17.83M | 7.61M |
| EBITDA | -57.11M | -62.37M | -97.89M | -153.79M | -152.81M | -124.86M |
| Net Income | -74.85M | -81.65M | -127.98M | -172.80M | -162.96M | -131.94M |
Balance Sheet | ||||||
| Total Assets | 249.45M | 264.50M | 275.80M | 313.80M | 400.12M | 463.46M |
| Cash, Cash Equivalents and Short-Term Investments | 156.71M | 168.95M | 158.69M | 203.32M | 287.50M | 339.49M |
| Total Debt | 101.61M | 101.25M | 201.86M | 136.19M | 103.23M | 37.81M |
| Total Liabilities | 137.77M | 137.54M | 248.98M | 190.91M | 154.13M | 89.38M |
| Stockholders Equity | 111.69M | 126.95M | 26.82M | 122.89M | 245.99M | 374.08M |
Cash Flow | ||||||
| Free Cash Flow | -34.25M | -47.13M | -117.22M | -134.81M | -154.05M | -133.37M |
| Operating Cash Flow | -33.51M | -46.33M | -116.30M | -131.37M | -145.73M | -130.26M |
| Investing Cash Flow | -11.71M | -97.68M | 103.94M | 83.03M | -66.30M | -142.51M |
| Financing Cash Flow | 348.00K | 55.50M | 67.87M | 43.65M | 72.90M | 160.15M |
Outset Medical Technical Analysis
Negative
4.35
Price Trends
4.41
Negative
4.08
Positive
6.28
Negative
Market Momentum
0.07
Positive
51.16
Neutral
48.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OM, the sentiment is Negative. The current price of 4.35 is below the 20-day moving average (MA) of 4.56, below the 50-day MA of 4.41, and below the 200-day MA of 6.28, indicating a bearish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 51.16 is Neutral, neither overbought nor oversold. The STOCH value of 48.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OM.
Outset Medical Risk Analysis
Outset Medical disclosed 79 risk factors in its most recent earnings report. Outset Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Outset Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $350.25M | 34.34 | 22.14% | ― | 16.79% | 45.17% | |
54 Neutral | $79.99M | -1.02 | -55.88% | ― | 2.01% | 85.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $174.63M | -7.06 | -12.90% | ― | 3.39% | 19.78% | |
47 Neutral | $136.39M | -2.59 | -120.77% | ― | 11.73% | 8.07% | |
46 Neutral | $80.72M | -1.04 | -47.09% | ― | 25.74% | -26.25% | |
42 Neutral | $30.67M | -0.70 | -77.48% | ― | -7.88% | -5535.71% |
* Healthcare Sector Average
OM
Outset Medical
4.32
-16.41
-79.16%
ARAY
Accuray
0.26
-1.10
-81.10%
ELMD
Electromed
42.30
20.50
94.04%
INGN
Inogen
6.45
-0.65
-9.15%
NNOX
Nano-X Imaging
1.16
-3.96
-77.34%
CVRX
CVRx
5.14
-0.90
-14.90%
Outset Medical Corporate Events
Business Operations and StrategyProduct-Related Announcements
Outset Medical Secures Multi‑Year HCA Hemodialysis Agreement
Positive
Jun 17, 2026
On June 14, 2026, Outset Medical, Inc. signed an amendment to its purchasing agreement with HCA Management Services, L.P., originally dated May 1, 2020, under which HCA will refresh its existing fleet of Tablo Hemodialysis Systems by purchasing ne...
Executive/Board ChangesShareholder Meetings
Outset Medical Shareholders Back Board and Governance Measures
Positive
Jun 5, 2026
On June 4, 2026, Outset Medical held its annual meeting of stockholders virtually, with a quorum representing roughly three-quarters of its 18.5 million outstanding shares. Shareholders elected Brent D. Lang and Karen Prange as Class III directors...
Executive/Board Changes
Outset Medical Announces Executive Vice President Marc Nash Departure
Neutral
May 29, 2026
On May 26, 2026, Outset Medical, Inc. announced that Marc Nash, its Executive Vice President of RD, Operations and Service, had informed the company of his decision to leave effective June 5, 2026, to pursue other professional opportunities. The c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.